Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022
NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Synaptogenix, Inc. ( Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today commented on the positive Phase 3 trial results for Lecanemab announced last night by Eisai and Biogen.
Read more at prnewswire.com